No Data
No Data
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Shandong Xinhua Pharmaceutical Eyes Stake in Nutritional Oil Refining Firm
Announcement highlights | Longfor Group's sales exceeded 90 billion yuan this year; Mao Geping announced the lottery results, listed this morning.
In the first 11 months, longfor group achieved a total contract sales amount of 93 billion yuan, with contract sales of 8.5 billion yuan in November; cspc pharma's application for marketing approval for SYHX2011 to treat advanced breast cancer was accepted.
SHANDONG XINHUA (00719) intends to acquire no more than 75% of the equity of Noah Saint New (Taicang) Biotechnology to improve the Omega-3 Industry Chain.
Shandong Xinhua (00719) announced that to improve the group's industry chain and supply chain, it is promoting the high-quality development of the health industry...
Express News | Shandong Xinhua Pharmaceutical - Novosanaeuropeb.v. to Sell Not More Than 75% of Novosana (Taicang) Co
Express News | Shandong Xinhua Pharmaceutical - Acquisition Letter of Intent in Relation to Acquisition of a Co
No Data
whqqq : Will more capital flow into the Hong Kong market after the delisting crisis?
HopelessChi whqqq : future is solid red. must be some amazing news crashing the future of HSI/HST
whqqq HopelessChi : What's the bad news?
海纳百川 whqqq : It will take longer for the market to recover; currently, it is still mainly bearish
whqqq 海纳百川 : OKAY...Thank you for your answer